Open access
Open access
Powered by Google Translator Translator

RCT: A single dose of a novel adenovirus type 5 vectored SARS-CoV-2 vaccine was safe and had 57.5% efficacy against symptomatic Covid-19 and 91.7% efficacy against severe disease in adults.

13 Jan, 2022 | 08:44h | UTC

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial – The Lancet

Commentaries:

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine – The Lancet

Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease – The Lancet

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.